validation set

validation set

Decision-making A group of Pts with a clinical finding of interest–eg, chest pain, who are studied prospectively in order to verify facets of their disease that had been previously identified as possible predictors of outcome. See Derivation set.
Mentioned in ?
References in periodicals archive ?
A single IHC-defined GH-expressing adenoma in the validation set (V8), from a patient with a clinically defined nonfunctioning adenoma, did not demonstrate excess GH on quantitative tissue analysis.
This analysis was carried out in 2 sets: (a) a training set consisting of 84 seminal plasma samples from 30 patients with nonobstructive azoospermia, 30 patients with asthenozoospermia, and 24 fertile control individuals; and (b) a validation set consisting of seminal plasma samples from an additional 126 infertile patients and 44 fertile controls.
Distribution of Laboratory Size (by Accessions) Relative to Validation Practices for the Most Recently Introduced Non-US Food and Drug Administration-Approved, Nonpredictive Immunohistochemistry Assay N 10th Pctl Median 90th Pctl Were weakly or focally positive cases included in the initial assay validation set (P = .
This analysis was carried out in 2 phases: (a) the biomarker-selection phase, in which serum samples from 36 ESCC patients treated at Jinling Hospital or Yanggongjing Hospital formed the training set, and (b) the biomarker-validation phase, in which serum samples from an additional 113 ESCC patients from Jinling Hospital or the Cancer Hospital of Jiangsu Province formed the validation set.
93 correlation coefficient), while in the validation set, a 0.
The PPV, the efficiency, and the resultant review rate were calculated for the validation set using the optimized criteria.
Patients were prospectively recruited from viral liver clinics in different tertiary referral centers; the training set was recruited from Sir Charles Gairdner Hospital (Perth, Australia) and the validation set from Westmead Hospital and Royal Prince Alfred Hospital (Sydney, Australia).
16,17) If the positive samples in the validation set are enriched with weakly positive specimens, as we propose, we believe that laboratories with at least 90% positive agreement at the time of assay validation under these conditions are likely to detect considerably more than 90% of ER-positive specimens in clinical practice.
Plasma concentration--time data for the validation set were used to evaluate the optimal sampling strategies.
The two extra mixtures were added to make the validation set more representative.